PTPN1 and ACTN1

Number of citations of the paper that reports this interaction (PubMedID 16291744)
21

Data Source:
HPRD (in vivo, in vitro)

		PTPN1	ACTN1
Description		protein tyrosine phosphatase non-receptor type 1	actinin alpha 1
Image
GO Annotations	Cellular Component	Cytoplasm Mitochondrial Matrix Early Endosome Endoplasmic Reticulum Cytosol Plasma Membrane Mitochondrial Crista Protein-containing Complex Sorting Endosome Cytoplasmic Side Of Endoplasmic Reticulum Membrane	Stress Fiber Ruffle Extracellular Region Extracellular Space Cytoplasm Cytosol Actin Filament Plasma Membrane Brush Border Cell-cell Junction Fascia Adherens Focal Adhesion Z Disc Cell Junction Cortical Actin Cytoskeleton Platelet Alpha Granule Lumen Pseudopodium Cell Projection Extracellular Exosome Glutamatergic Synapse
	Molecular Function	RNA Binding Protein Tyrosine Phosphatase Activity Insulin Receptor Binding Protein Binding Zinc Ion Binding Enzyme Binding Protein Kinase Binding Receptor Tyrosine Kinase Binding Cadherin Binding Ephrin Receptor Binding Protein Phosphatase 2A Binding	Double-stranded RNA Binding Integrin Binding Calcium Ion Binding Protein Binding Vinculin Binding Nuclear Receptor Coactivator Activity Protein Homodimerization Activity Transmembrane Transporter Binding Actin Filament Binding Structural Constituent Of Postsynapse
	Biological Process	Protein Dephosphorylation Insulin Receptor Signaling Pathway Regulation Of Signal Transduction Negative Regulation Of Signal Transduction Regulation Of Endocytosis Negative Regulation Of Vascular Endothelial Growth Factor Receptor Signaling Pathway Endoplasmic Reticulum Unfolded Protein Response Actin Cytoskeleton Reorganization Regulation Of Intracellular Protein Transport Cellular Response To Unfolded Protein Peptidyl-tyrosine Dephosphorylation Platelet-derived Growth Factor Receptor-beta Signaling Pathway IRE1-mediated Unfolded Protein Response Negative Regulation Of MAP Kinase Activity Positive Regulation Of JUN Kinase Activity Negative Regulation Of Insulin Receptor Signaling Pathway Regulation Of Type I Interferon-mediated Signaling Pathway Growth Hormone Receptor Signaling Pathway Via JAK-STAT Positive Regulation Of Protein Tyrosine Kinase Activity Negative Regulation Of ERK1 And ERK2 Cascade Regulation Of Hepatocyte Growth Factor Receptor Signaling Pathway Negative Regulation Of Endoplasmic Reticulum Stress-induced Intrinsic Apoptotic Signaling Pathway Positive Regulation Of IRE1-mediated Unfolded Protein Response Negative Regulation Of PERK-mediated Unfolded Protein Response Peptidyl-tyrosine Dephosphorylation Involved In Inactivation Of Protein Kinase Activity Positive Regulation Of Receptor Catabolic Process	Actin Filament Organization Actin Cytoskeleton Organization Platelet Activation Platelet Formation Platelet Morphogenesis Regulation Of Apoptotic Process Positive Regulation Of Transcription, DNA-templated Focal Adhesion Assembly Actin Filament Bundle Assembly Negative Regulation Of Cellular Component Movement Actin Filament Network Formation Muscle Cell Development Platelet Aggregation Postsynapse Organization
Pathways		Integrin signaling Negative regulation of MET activity Regulation of IFNG signaling PTK6 Down-Regulation MECP2 regulates neuronal receptors and channels Regulation of IFNA signaling Growth hormone receptor signaling Growth hormone receptor signaling	Platelet degranulation Syndecan interactions Nephrin family interactions Regulation of cytoskeletal remodeling and cell spreading by IPP complex components RHOD GTPase cycle RHOBTB2 GTPase cycle RHOF GTPase cycle
Drugs		3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid, {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid Compound 19 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid 2-(Oxalyl-Amino)-Benzoic Acid {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid) Novo Nordisk a/S Compound N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid PNU177836 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid L-cysteic acid 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID ISIS 113715 Trodusquemine Ertiprotafib 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID ISOTHIAZOLIDINONE ANALOG 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid p-Benzoyl-L-phenylalanine 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid	Human calcitonin Copper
Diseases
GWAS		Basophil count ( 32888494) Colorectal cancer ( 30529582 31826910) Colorectal cancer or advanced adenoma ( 30510241) Eosinophil counts ( 32888494) Eosinophil percentage of white cells ( 32888494) Intraocular pressure ( 29617998 29785010 31959993 30054594) Lymphocyte percentage of white cells ( 32888494) Thyroid stimulating hormone levels ( 30843173) Vitiligo ( 27723757)	Asthma ( 31959851) Cognitive decline rate in late mild cognitive impairment ( 26252872) Feeling fed-up ( 29500382) Feeling hurt ( 29500382) Fibrinogen ( 23969696) Fibrinogen levels ( 28107422) High light scatter reticulocyte count ( 32888494) Lack of perseverance ( 30718321) Mean platelet volume ( 32888494 27863252) Medication use (drugs used in diabetes) ( 31015401) Mosquito bite size ( 28199695) Neurociticism ( 29500382) Periodontitis (Mean PAL) ( 24024966) Platelet count ( 26805783 29403010 32888494) Platelet distribution width ( 32888494 27863252) Plateletcrit ( 32888494) Prostate cancer ( 23535732) Rheumatoid arthritis (ACPA-positive) ( 23143596) Smoking behavior ( 19247474) Urinary albumin excretion ( 30220432)
Interacting Genes		66 interacting genes: ACTN1 AGR3 AKT1 AQP6 ASS1 BCAR1 BCAS3 BCR CAPN2 CASC3 CASZ1 CAV1 CCL5 CDH13 CDH2 CDK1 CLK1 CLK2 COP1 CRK CSNK2A1 CSNK2A2 CTNNB1 DIRAS3 EGFR ELOVL4 ESR1 FGFR1 GHR GLRX GRB2 GSK3B IGF1R INSR IRS1 JAK2 KLK7 LAT LRATD2 LTK MAPK1 MRC2 NFKBIA NTRK1 NTRK2 NTRK3 PDGFRB PIAS1 PIGP PIN1 RHOBTB2 RRAS2 SNAI1 SRC STAM2 STAT3 STAT5A STAT5B THRSP TIMMDC1 TMEM31 TMEM41A TMEM86B TRPV6 TYK2 VPS45	92 interacting genes: ACTN2 ACTN3 ADORA2A APC APPBP2 ATXN2 ATXN7 C14orf119 CACNA1A CAMK2A CBY2 CDK5 CDK5R1 CDK5R2 CLIC5 COIL COL17A1 CSRP1 CSRP3 CTNNA1 DDIAS DYNLT1 EIF2S1 EPM2AIP1 ERBIN FBP1 FXN FXR1 GADD45G GFI1B GIPC1 GIT2 GRIA4 GRIN2A GRM5 GTF2H1 HSPB1 ICAM5 ITGB1 KAT2B KCTD6 KPNA2 LINC01554 LNX1 LPP MAGEA11 MAP2 MAP3K1 MED14 MICALL2 MTDH MTNR1A MTNR1B MYOT MYOZ1 MYOZ2 MYOZ3 NEBL NKAPD1 NR1H3 NUMBL OAS1 PALLD PDHX PDLIM1 PDLIM5 PIAS4 PKD1 PKN1 PLD2 PSEN1 PSMA1 PTK2 PTPN1 PTPN6 PYGB RAVER1 RPS27 SIRPA SLC2A4 SORBS2 SRC SSX2IP SYNPO2L TES TSC1 TTN TXN USP2 VCL XRCC4 ZYX
Entrez ID		5770	87
HPRD ID		01477	00020
Ensembl ID		ENSG00000196396	ENSG00000072110
Uniprot IDs		A8K3M3 B4DSN5 P18031	A0A024R694 A0A7I2V4Y4 P12814
PDB IDs		1A5Y 1AAX 1BZC 1BZH 1BZJ 1C83 1C84 1C85 1C86 1C87 1C88 1ECV 1EEN 1EEO 1G1F 1G1G 1G1H 1G7F 1G7G 1GFY 1I57 1JF7 1KAK 1KAV 1L8G 1LQF 1NL9 1NNY 1NO6 1NWE 1NWL 1NZ7 1OEM 1OEO 1OES 1OET 1OEU 1OEV 1ONY 1ONZ 1PA1 1PH0 1PTT 1PTU 1PTV 1PTY 1PXH 1PYN 1Q1M 1Q6J 1Q6M 1Q6N 1Q6P 1Q6S 1Q6T 1QXK 1SUG 1T48 1T49 1T4J 1WAX 1XBO 2AZR 2B07 2B4S 2BGD 2BGE 2CM2 2CM3 2CM7 2CM8 2CMA 2CMB 2CMC 2CNE 2CNF 2CNG 2CNH 2CNI 2F6F 2F6T 2F6V 2F6W 2F6Y 2F6Z 2F70 2F71 2FJM 2FJN 2H4G 2H4K 2HB1 2HNP 2HNQ 2NT7 2NTA 2QBP 2QBQ 2QBR 2QBS 2VEU 2VEV 2VEW 2VEX 2VEY 2ZMM 2ZN7 3A5J 3A5K 3CWE 3D9C 3EAX 3EB1 3EU0 3I7Z 3I80 3QKP 3QKQ 3SME 3ZMP 3ZMQ 3ZV2 4BJO 4I8N 4QAH 4QAP 4QBE 4QBW 4Y14 4ZRT 5K9V 5K9W 5KA0 5KA1 5KA2 5KA3 5KA4 5KA7 5KA8 5KA9 5KAA 5KAB 5KAC 5KAD 5QDE 5QDF 5QDG 5QDH 5QDI 5QDJ 5QDK 5QDL 5QDM 5QDN 5QDO 5QDP 5QDQ 5QDR 5QDS 5QDT 5QDU 5QDV 5QDW 5QDX 5QDY 5QDZ 5QE0 5QE1 5QE2 5QE3 5QE4 5QE5 5QE6 5QE7 5QE8 5QE9 5QEA 5QEB 5QEC 5QED 5QEE 5QEF 5QEG 5QEH 5QEI 5QEJ 5QEK 5QEL 5QEM 5QEN 5QEO 5QEP 5QEQ 5QER 5QES 5QET 5QEU 5QEV 5QEW 5QEX 5QEY 5QEZ 5QF0 5QF1 5QF2 5QF3 5QF4 5QF5 5QF6 5QF7 5QF8 5QF9 5QFA 5QFB 5QFC 5QFD 5QFE 5QFF 5QFG 5QFH 5QFI 5QFJ 5QFK 5QFL 5QFM 5QFN 5QFO 5QFP 5QFQ 5QFR 5QFS 5QFT 5QFU 5QFV 5QFW 5QFX 5QFY 5QFZ 5QG0 5QG1 5QG2 5QG3 5QG4 5QG5 5QG6 5QG7 5QG8 5QG9 5QGA 5QGB 5QGC 5QGD 5QGE 5QGF 5T19 6B8E 6B8T 6B8X 6B8Z 6B90 6B95 6BAI 6CWU 6CWV 6NTP 6OL4 6OLQ 6OLV 6OMY 6PFW 6PG0 6PGT 6PHA 6PHS 6PM8	2EYI 2EYN 2N8Y 2N8Z
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?